Ads
related to: anoro ellipta
Search results
GSK Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 4 weeks agoWe expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 2 months agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
Glaxo (GSK) Up 3.1% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1%...
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for GSK (GSK). Shares have added about 6.7% in...
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
Zacks via Yahoo Finance· 2 years agoEntasis Therapeutics Holdings Inc. ETTX announced that it has signed a definitive merger agreement...
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
Zacks via Yahoo Finance· 2 years agoGSK plc GSK reported third-quarter 2022 adjusted earnings of $1.09 per American depositary share...
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 3 months agoRevenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
Zacks via Yahoo Finance· 2 months agoGSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month...
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The...
Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million
GuruFocus.com via Yahoo Finance· 7 months agoInnoviva Inc (NASDAQ:INVA) reported net income of $82.0 million for Q3 2023, a significant decrease from $265.5 million in Q3 2022. The company received GSK royalties of $57.0 million and net ...
